Effective early prediction of acute pancreatitis (AP) severity remains an unmet clinical need due to limited molecular characterization of systemic immune responses. We performed integrated single-cell RNA sequencing with T- and B-cell receptor profiling on peripheral blood mononuclear cells from AP patients (n = 7) at days 1, 3, and 7 after admission. Immune landscape analysis revealed marked inter-patient heterogeneity, with a distinct expansion of MZB1-expressing plasma cells that were strongly associated with complicated AP and recovery. Functional validation in an independent cohort (n = 14) confirmed disease-associated plasma cell markers, alongside altered serum immunoglobulin and cytokine profiles (n = 32). From these findings, we established a nine-gene B-cell-derived transcriptomic signature (S100A8, DUSP1, JUN, HBA2, FOS, CYBA, JUNB, S100A9, and WDR83OS) predictive of AP severity. This model demonstrated high discriminative performance in internal validation (n = 114; AUROC > 0.95, superior to standard clinical scoring systems), and sustained accuracy in external validation cohorts of AP (n = 87) and AP combined with non-AP sepsis (n = 174) for predicting persistent organ failure. Our study identifies a mechanistic and predictive role for MZB1⺠plasma cells in AP pathogenesis, offering a novel immune-based stratification strategy with potential for precision clinical management.
Single-Cell Transcriptomic Atlas of Peripheral Blood Reveals B-Cell-Driven Signature Predictive of Acute Pancreatitis Severity.
外周血单细胞转录组图谱揭示了B细胞驱动的特征,可预测急性胰腺炎的严重程度
阅读:4
作者:Xie Rongli, Xiao Guohui, Yang Kaige, Wang Xiaofeng, Chen Cong, Ding Min, Zhou Tong, Mukherjee Rajarshi, Sutton Robert, Chen Erzhen, Chen Ying, Huang Wei, Xu Dan, Fei Jian
| 期刊: | MedComm | 影响因子: | 10.700 |
| 时间: | 2025 | 起止号: | 2025 Sep 14; 6(10):e70350 |
| doi: | 10.1002/mco2.70350 | 研究方向: | 细胞生物学 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
